Free access supported by contributions and sponsoring — share your knowledge or support us financially
Search / Compare / Validate Lab equipment & Methods

Immunoseq

Manufactured by Adaptive Biotechnologies
Sourced in United States
About the product

ImmunoSEQ is a high-throughput sequencing platform that enables comprehensive profiling of T-cell and B-cell receptor repertoires. It provides a quantitative and unbiased assessment of immune cell populations.

Automatically generated - may contain errors

Market Availability & Pricing

The immunoSEQ Assay by Adaptive Biotechnologies is the industry gold standard in immunosequencing. It is commercially available and helps researchers make discoveries in various areas such as oncology, autoimmune disorders, infectious diseases, neurobiology, transplant, and basic immunology.

The immunoSEQ Assay can identify millions of T- and B-cell receptors from a single sample in exquisite detail. It is offered as a Service or Kit and is used to ask and answer translational research questions and discover new prognostic and relevant signals in clinical research. The immunoSEQ Assay provides quantitative, scalable, and reproducible sequencing results along with access to a powerful, easy-to-use analysis tools via the immunoSEQ Analyzer software.

In December 2020, Adaptive Biotechnologies partnered with Q² Solutions to market the immunoSEQ Assay, expanding its availability to pharmaceutical clients.

Specific pricing information is not publicly disclosed. For detailed pricing, please contact Adaptive Biotechnologies directly or consult authorized distributors.

Need Operating Instructions, SDS, or distributor details? Just ask our AI Agent.

Is this product still available?

Get pricing insights and sourcing options

The spelling variants listed below correspond to different ways the product may be referred to in scientific literature.
These variants have been automatically detected by our extraction engine, which groups similar formulations based on semantic similarity.

95 protocols using «immunoseq»

1

T-cell Receptor Sequencing for Diversity Analysis

2025
To determine T cell diversity and clonality, frozen EDTA-anticoagulated blood and FFPE tissue specimens were sent to Adaptive Biotechnologies (WA, USA) for ImmunoSEQ - T-cell Receptor Sequencing (TCR) sequencing. Extracted genomic DNA was amplified in a bias-controlled multiplex PCR, followed by high-throughput sequencing. Sequences were collapsed and filtered in order to identify and quantitate the absolute abundance of each unique TCRβ CDR3 region for further analysis as previously described65 (link)–67 (link). Data was analyzed using the ImmunoSEQ Analyzer software platform. Morisita index is a modified correlation comparing both shared clones and relative abundance of clones between two samples. Values can range from 1 (identical) to 0 (disparate) when comparing repertoires68 (link). Peripheral T cells fraction is calculated as the total T cells divided by an estimate of the total number of nucleated cells based on mass. Higher T cell fraction indicates more recruitment and activation of T cells in peripheral blood. The pairwise comparison of shared clones between subjects assessed the overlap of the top 100 most abundant clones for all 10 possible pairs of blood samples within each treatment group (n = 5), with each pair resulting in a data point representing the number of shared top 100 clones. Dearth of “public clones” may indicate increase in number or diversity of tumor antigens within each subject. Simpson Clonality69 quantifies the extent to which one or few clones dominate the repertoire. It ranges from 0 (even distribution) to 1 (monoclonal) and is robust to sequencing depth. Here Simpson Clonality is defined as the square root of Simpson’s index.
+ Open protocol
+ Expand Check if the same lab product or an alternative is used in the 5 most similar protocols
2

T-cell Receptor Sequencing for Diversity Analysis

2025
To determine T cell diversity and clonality, frozen EDTA-anticoagulated blood and FFPE tissue specimens were sent to Adaptive Biotechnologies (WA, USA) for ImmunoSEQ - T-cell Receptor Sequencing (TCR) sequencing. Extracted genomic DNA was amplified in a bias-controlled multiplex PCR, followed by high-throughput sequencing. Sequences were collapsed and filtered in order to identify and quantitate the absolute abundance of each unique TCRβ CDR3 region for further analysis as previously described65 (link)–67 (link). Data was analyzed using the ImmunoSEQ Analyzer software platform. Morisita index is a modified correlation comparing both shared clones and relative abundance of clones between two samples. Values can range from 1 (identical) to 0 (disparate) when comparing repertoires68 (link). Peripheral T cells fraction is calculated as the total T cells divided by an estimate of the total number of nucleated cells based on mass. Higher T cell fraction indicates more recruitment and activation of T cells in peripheral blood. The pairwise comparison of shared clones between subjects assessed the overlap of the top 100 most abundant clones for all 10 possible pairs of blood samples within each treatment group (n = 5), with each pair resulting in a data point representing the number of shared top 100 clones. Dearth of “public clones” may indicate increase in number or diversity of tumor antigens within each subject. Simpson Clonality69 quantifies the extent to which one or few clones dominate the repertoire. It ranges from 0 (even distribution) to 1 (monoclonal) and is robust to sequencing depth. Here Simpson Clonality is defined as the square root of Simpson’s index.
+ Open protocol
+ Expand Check if the same lab product or an alternative is used in the 5 most similar protocols
3

Immunosequencing of T-cell and B-cell Receptors

2025
Rearranged TCRB and IGH loci analysis was initially performed (immunoSEQ, Adaptive Biotechnologies, Washington, USA) as reported previously [31 (link), 32 (link)]. Bulk T cell beta chain and B cell heavy chain receptor sequences and sorted subsets of B cell heavy chain receptors were performed as previously described [33 (link)]. Repertoire analysis was performed using in-house bioinformatics available in online supplemental methods.
+ Open protocol
+ Expand Check if the same lab product or an alternative is used in the 5 most similar protocols
4

Lung Tissue Dissociation and TCRB Sequencing

2024
Lungs were harvested at 14 weeks post Ad-cre instillation and dissociated. DNA was extracted from lung tissue using the Quick-DNA/RNA Microprep Plus Kit (Zymo Research) and 3 µg was sent for TCRB sequencing using immunoSEQ (Adaptive Biotechnologies).
+ Open protocol
+ Expand Check if the same lab product or an alternative is used in the 5 most similar protocols
5

Profiling T-cell Receptor Repertoire

2024
Peptides with demonstrated immunogenicity by ELISpot assay were used to stimulate PBMCs as described above under ELISpot. Control PBMCs were stimulated with irrelevant peptides or media only. On day 12, cells were harvested and genomic DNA was extracted and purified from cells using the QIAGEN Blood and Tissue Kit (Qiagen, Germantown, MD). TCRVβ CDR3 regions were amplified and sequenced using ImmunoSEQ (Adaptive Biotechnologies, Seattle, WA). Data [77 ] were analyzed with ImmunoSEQ software and GraphPad Prism 9. Alternatively,
RNA was extracted instead of DNA using the RNeasy Plus Kit (Qiagen, Germantown, MD). Bulk RNA was stored in nuclease-free water at − 80 °C until subsequent use. cDNA libraries of each sample’s TCR Vα and Vβ chains were prepared using an amplification bias-controlled multiplex PCR using the SMART-Seq Human TCR (with UMIs) kit (Takara Bio, San Jose, CA) according to the manufacturer’s instructions. Sequencing was performed on NovaSeq6000 or NovaSeq X Plus instruments (Illumina, San Diego, CA). Bulk TCR sequencing data generated with the SMART-Seq Human TCR kit were processed using the Cogent NGS Immune Profiler software v1.6 (Takara Bio, San Jose, CA) with default parameters and receptor type argument (-r) “TCRv2” to carry out UMI based calling and quantification of clonotypes. Analysis of clonotype frequencies was restricted to TRB CDR3 sequences.
+ Open protocol
+ Expand Check if the same lab product or an alternative is used in the 5 most similar protocols

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!

🧪 Need help with an experiment or choosing lab equipment?
I search the PubCompare platform for you—tapping into 40+ million protocols to bring you relevant answers from scientific literature and vendor data.
1. Find protocols
2. Find best products for an experiment
3. Validate product use from papers
4. Check Product Compatibility
5. Ask a technical question
Want to copy this response? Upgrade to Premium to unlock copy/paste and export options.